Incidence and Risk Factors for Extensively Drug-Resistant Tuberculosis in Delhi Region

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Porwal, Chhavi ^a   Kaushik, Amit ^a   Makkar, Nayani ^a   Banavaliker, Jayant N ^b   Hanif, Mahmud ^c   Singla, Rupak ^d   Bhatnagar, Anuj K ^b   Behera, Digambar ^d   Pande, Jitendra Nath ^e   Singh, Urvashi B ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Rajan Babu Institute for Pulmonary Medicine and Tuberculosis   (India)

^c New Delhi Tuberculosis Centre   (India)

^d Lala Ram Sarup Institute of Tuberculosis and Respiratory Diseases   (India)

^e SITARAM BHARTIA INSTITUTE OF SCIENCE AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG MEGADOSE; DRUG USE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FAMILY HISTORY; FEMALE; HUMAN; INCIDENCE; INDIA; INFECTION RISK; LOW DRUG DOSE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; RISK ASSESSMENT; SOCIAL STATUS; SPUTUM CULTURE;

ADULT; AMIKACIN; ANTITUBERCULAR AGENTS; CAPREOMYCIN; ETHIONAMIDE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; INCIDENCE; INDIA; ISONIAZID; MALE; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; PREVALENCE; RIFAMPIN; RISK FACTORS; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 84873489187     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055299     Document Type: Article

References (29)

1. World Health Organization (2012) Global tuberculosis report; WHO/HTM/TB/2012.6, ISBN 978 92 4 156450 2. Available: http://www.who.int/tb/publications/global_report/en/index.html. Accessed 2013 Jan 5.
2. Migliori GB, Loddenkemper R, Blasi F, Raviglione MC, (2007) 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic? EurRespir J 29: 423-427.
3. Centers for Disease Control and Prevention (2006) "Notice to Readers: Revised Definition of Extensively Drug-R Tuberculosis". JAMA: the Journal of the American Medical Association (American Medical Association) 296 (23): 2792.
4. Grace Lin SY, Desmond E, Bonato D, Gross W, Siddiqi S, (2009) Multicenter Evaluation of Bactec MGIT 960 System for Second-Line Drug Susceptibility Testing of Mycobacterium tuberculosis Complex. J Clin Microbiol 47: 3630-3634.
5. Martin A, Groll AV, Fissette K, Palomino JC, Varaine F, et al. (2008) Rapid Detection of Mycobacterium tuberculosis Resistance to Second-Line Drugs by Use of the Manual Mycobacterium Growth Indicator Tube System. J Clin Microbiol 46: 3952-56.
6. World Health Organization (2010) Multidrug and Extensively Drug-resistant Tb (M/XDR-TB): 2010 Global report on surveillance and response (WHO/HTM/TB/2010.3).
7. Mondal R, Jain A, (2007) Extensively Drug-Resistant Mycobacterium tuberculosis, India. Emer Infectious Dis 13: 1429-31.
8. Paramasivan CN, Rehman F, Wares F, Sundar Mohan N, Sundar S, et al. (2010) First- and second-line drug resistance patterns among previously treated tuberculosis patients in India. Int J Tuberc Lung Dis 14: 243-246.
9. Sharma SK, George N, Kadhiravan T, Saha PK, Mishra HK, et al. (2009) Prevalence of extensively drug- resistant tuberculosis among patients with multidrug- resistant tuberculosis: a retrospective hospital-based study. Indian J Med Res 392-395.
10. Khanna A, Raj VS, Tarai B, Sood R, Pareek PK, et al. (2010) Emergence and Molecular Characterization of Extensively Drug-R Mycobacterium tuberculosis Clinical Isolates from the Delhi Region in India. Antimicrobial Agents and Chemotherapy 54: 4789-93.
11. Ajbani K, Rodrigues C, Shenai S, Mehta A, (2011) Can mutation detection accurately predict XDR- TB: study from a tertiary care centre India. J Clin Microbiol 49(4): 1588-90.
12. Balaji V, Daley P, Anand AA, Sudarsanam T, Michael JS, et al. (2010) Risk Factors for MDR and XDR-TB in a Tertiary Referral Hospital in India. Plos One 5(3): e9527.
13. Kent PT, Kubica GP (1985) Public health mycobacteriology: a guide for the level III laboratory. Atlanta, Ga.: U.S. Department of Health and Human Services/Public Health Service/Centers for Disease Control.
14. Siddiqi SH, RuschGerdes S (2006) MGIT procedure manual. Geneva, Switzerland: Foundation for Innovative New Diagnostics, 2006.
15. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, et al. (2008) Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. Int J Tuberc Lung Dis 12: 1449-1455.
16. Rüsch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S (2006) Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of M. tuberculosis to classical second line drugs and newer antimicrobials. J ClinMicrobiol 688-92.
17. World Health Organization (2008) Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs (WHO/HTM/TB/2008.392).
18. Banerjee R, Allen J, Westenhouse J, Oh P, Elms W, et al. (2008) Extensively drug-R tuberculosis in california, 1993-2006. Clin Infect Dis 47: 450-457.
19. World Health Organization (2006) Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 81: 430-432.
20. Raviglione M, Smith IM, (2007) XDR tuberculosis-implications for global public health. N Engl J Med 356: 656-659.
21. Jain A, Dixit P, (2008) Multidrug resistant to extensively drug resistant tuberculosis: What is next? J Biosci 33: 605-16.
22. Singh S, Sankar MM, Gopinath K, (2007) High rate of extensively drug- resistant tuberculosis in Indian AIDS patients. AIDS 21: 2345-7.
23. Singh JA, Upshur R, Padayatchi N, (2007) XDR-TB in South Africa: no time for denial or complacency. PLoS medicine 4: e50.
24. Jeon CY, Hwang SH, Min JH, Prevots DR, Goldfeder LC, et al. (2008) Extensively Drug- resistant Tuberculosis in South Korea: Risk Factors and Treatment Outcomes among Patients at a Tertiary Referral Hospital. Clinical Infectious Diseases 46: 42-9.
25. Dalton T, Cegielski P, Akksilp P, Asencios L, Caoili JC, et al. (2012) Prevalence of and risk factors for resistance to second-line drugs in people with multidrug- resistant tuberculosis in eight countries: a prospective cohort study. Lancet 380: 1406-1417.
26. Chan ED, Strand MJ, Iseman MD, (2009) Multidrug- resistant Tuberculosis (TB) resistant to Fluoroquinolones and Streptomycin but Susceptible to Second-Line Injection Therapy Has a Better Prognosis than Extensively Drug- resistant TB. Clinical Infectious Diseases 48: e50-2.
27. Mlambo CK, Warren RM, Poswa X, Victor TC, Duse AG, et al. (2008) Genotypic diversity of extensively drug- resistant tuberculosis (XDR-TB) in South Africa. Int J Tuberc Lung Dis 12: 99-104.
28. Maus CE, Plikaytis BB, Shinnick TM, (2005) Molecular Analysis of Cross-Resistance to Capreomycin, Kanamycin, Amikacin, and Viomycin in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 49: 3192-3197.
29. Jassal M, Bishai WR, (2009) Extensively drug-R tuberculosis. Lancet Infect Dis 9: 19-30.